

October 30, 2021

To
The BSE Limited
Corporate Relation Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001.

Sub: Outcome of Board Meeting held on October 30, 2021
Scrip Code: 542724

Dear Sir/Madam,



We are to inform you that a Meeting of Board of Directors of the Company was convened today i.e. October 30, 2021 (Commenced at 1:00 P.M. and Concluded at: 2:30 P.M.), wherein the Unaudited Financial Results (IND AS) for the quarter and half year ended September 30, 2021 were considered and approved.

Accordingly, we are sending herewith copy of Unaudited Financial Results (IND AS) along with copy of Limited Review Report given by the Statutory Auditors of the Company for the quarter and half year ended September 30, 2021.

Kindly take the same on your records.

Thanking You.

Yours Faithfully,
For, EARUM PHARMACEUTICALS LIMITED



PRIYA RAVAL
COMPANY SECRETARY &
COMPLIANCE OFFICER

EARUM PHARMCEUTICALS LIMITED

CIN: 24230GJ2012PLC071299

Registered Office: "G-1 V R COMPLEX, Nr.SANATHAL CROSS ROAD,S P RING ROAD,SANATHAL,AHMEDABAD-382210"

Phone: +91 79 48402525, E mail: earumpharma@gmail.com, Website: www.earumpharma.com

Statement of Unaudited Financial Results For The Quarter and Half Year Ended on 30.09.2021

All amount in Rs. Lacs unless otherwise stated

Sr. No.	Particulars	3 months Ended	3 months Ended	Corresponding	6 Months ended	Corresponding	Year Ended
		30.09.2021	30.06.2021	3 months Ended	30.09.2021	6 Month Ended	31.03.2021
		(Unaudited)	(Unaudited)	30.09.2020	(Unaudited)	30.09.2020	(Audited)
				(Unaudited)		(Unaudited)	
1	Revenue from operations						
	(a) Net sales/Income from operations (Net of excise duty)	842.29	298.74	910.79	1,141.03	3,885.09	4,108.37
	(b) Other Income	220.04	8.27	80.90	228.31	298.75	893.20
	Total Revenue	1,062.33	307.01	991.69	1,369.34	4,183.84	5,001.57
2	Expenses						
	(a) Cost of materials consumed			-	-	-	-
	(b) Purchase of Stock in Trade	388.29	304.44	909.58	692.73	3,542.75	4,834.16
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	98.18	328.04	100.77	426.22	525.04	(206.94)
	(d) Employee benefits expense	0.66	1.49	9.31	2.15	15.88	29.30
	(e) Finance Cost	0.96	7.26	46.50	8.22	45.66	93.05
	(f) Depreciation and amortisation expense	4.97	3.15	-	8.12	7.86	12.30
	(g) Other expenses	29.30	3.93	24.23	33.23	209.36	227.94
	(i) Power Expenses			-	-	-	-
	(j) Fuel Expenses			-	-	-	-
	Total expenses	522.36	648.31	1,090.39	1,170.67	4,346.55	4,989.81
3	Profit/(Loss) from operations before an Exceptional and Extra ordinary items and Tax (1-2)	539.97	(341.30)	(98.70)	198.67	(162.71)	11.76
4	Exceptional Items			-	-	-	-
5	Profit/(Loss) from ordinary activities before an Extra Ordinary items and Tax (3 - 4)	539.97	(341.30)	(98.70)	198.67	(162.71)	11.76
6	Extra Ordinary Items			-	-	-	-
7	Profit/(Loss) from ordinary activities before tax (5 - 6)	539.97	(341.30)	(98.70)	198.67	(162.71)	11.76
8	Tax Expense (net)						
	- Current tax			-	-	-	2.94
	- Deffered tax			-	-	-	-
	Total Tax Expenses						2.94
9	Net Profit(Loss) for the Period from continuing operations	539.97	(341.30)	(98.70)	198.67	(162.71)	8.82
10	Profit(Loss) From Discontinuing operations before tax			-	-	-	-
11	Tax Expense of discontinuing Oprations			-	-	-	-
12	Net Profit(loss) from discontinuing Oprations after Tax			-	-	-	-
13	Profit(loss) for period before minority interest	539.97	(341.30)	(98.70)	198.67	(162.71)	8.82
14	Share of profits(loss) of subsidiary			-	-	-	0.29
15	Profit(loss) of minority Interest			-	-	-	-
16	Net Profit(loss) for the period	539.97	(341.30)	(98.70)	198.67	(162.71)	8.82
17	Details of Equity share capital						
	(a) Paid up Equity Share capital	1,233.58	616.79	616.79	1,233.58	616.79	616.79
	(b) face value of Equity share capital(in Rs.)	10.00	10.00	10.00	10.00	10.00	10.00
18	Details of Debt Securities						
	(a) Paid up Debt capital			-	-	-	-
	(b) face value of debt securities			-	-	-	-
19	Debentures redemption reserve			-	-	-	-
20	Earnings per share (before extra ordinary items) (of Rs. 10 each) (not annualised):						
	(a) Basic	4.38	-5.53	-1.60	1.56	-2.64	0.14
	(b) Diluted	4.38	-5.53	-1.60	1.56	-2.64	0.14
21	Earnings per share (after extra ordinary items) (of Rs. 10 each) (not annualised):						
	(a) Basic	4.38	-5.53	-1.60	1.56	-2.64	0.14
	(b) Diluted	4.38	-5.53	-1.60	1.56	-2.64	0.14

For, EARUM PHARMACEUTICALS LIMITED



BHUMISHTH PATEL
MANAGING DIRECTOR
DIN : 02516641

DATE : 30.10.2021
PLACE : AHMEDABAD

Statement of Assets and Liabilities for the period ended 30.09.2021

Particulars	As At 30.09.2021	As At 31.03.2021
	UNAUDITED	AUDITED
EQUITY AND LIABILITIES		
1 Shareholders' funds		
(a) Share capital	1,233.58	616.79
(b) Reserves and surplus	415.21	833.33
(c) Money Received against share warrants	-	-
Total Shareholders' funds	1,648.79	1,450.12
2 Share Application money pending allotment	-	-
3 Deferred Government Grants	-	-
4 Minority Interest	-	-
5 Non-current liabilities		
- Long-term borrowings	362.50	237.89
- Deferred tax liabilities (net)	1.07	1.07
- Foreign Currency Monetary Item translation difference liability account	-	-
- Other long-term liabilities	-	-
- Long-term provisions	-	-
Total Non-current liabilities	363.57	238.96
6 Current liabilities		
- Short-term borrowings	874.02	895.30
- Trade payables		
(A) Total outstanding dues of micro enterprises and small enterprises	-	-
(B) Total outstanding dues of creditors other than micro enterprise and small enterprises	269.57	129.42
- Other current liabilities	152.56	34.98
- Short-term provisions	38.17	38.16
Total Current liabilities	1,334.32	1,097.86
TOTAL EQUITY AND LIABILITIES	3,346.68	2,786.94
ASSETS		
1 Non-current assets		
(i) Fixed assets		
- Tangible assets	67.97	76.09
- Producing Properties	-	-
- Intangible Assets	-	-
- Preproducing Properties	-	-
- Tangible Assets Capital work-in-progress	-	-
- Intangible assts under development or work - in - progress	-	-
Total Fixed Assets	67.97	76.09
(ii) Non-current investments	-	-
(iii) Deferred tax assets (net)	-	-
(iv) Foreign currency monetary item translation difference asset account	-	-
(v) Long-term loans and advances	-	-
(vi) Other non-current assets	-	-
Total Non-current assets	67.97	76.09
2 Current assets		
- Current investments	-	-
- Inventories	1,120.14	1,546.35
- Trade receivables	2,068.43	1,067.30
- Cash and cash equivalents	0.47	5.85
- Short-term loans and advances	62.01	61.92
- Other current assets	27.66	29.43
Total Current assets	3,278.71	2,710.85
TOTAL - ASSETS	3,346.68	2,786.94



For, EARUM PHARMACEUTICALS LIMITED

BRUMISHVATH PATEL
MANAGING DIRECTOR
DIN : 02516641


DATE : 30.10.2021
PLACE : AHMEDABAD

CASHFLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30,2021

All amount in Rs. Lacs unless otherwise stated

	For the period Ended 30th September,2021	For the Period Ended 31st March,2021
Cash flows from operating activities		
Profit before taxation	198.67	11.76
Adjustments for:		
Depreciation	-	12.30
Investment income	-	-
Deferred tax Liability	-	-
Interest expense	8.22	93.05
Profit / (Loss) on the sale of property, plant & equipment	-	-
Working capital changes:		
(Increase) / Decrease in trade and other receivables	(1,001.13)	628.08
(Increase) / (Decrease) in inventories	426.21	(206.93)
(Increase) / (Decrease) in Short Term Loan & Advance	(0.09)	42.30
(Increase) / (Decrease) in Other Current Assets	1.77	62.39
Increase / (Decrease) in Trade payables	140.15	(1,021.82)
Increase / (Decrease) in Short term Provisions	0.01	(25.42)
Increase / (Decrease) in Other Current Liabilities	117.58	(79.89)
Cash generated from operations	(108.61)	(484.18)
Interest paid	(8.22)	(93.05)
Income taxes paid	-	(2.94)
Dividends paid	-	-
Net cash from operating activities	(116.83)	(580.17)
Cash flows from investing activities		
Business acquisitions, net of cash acquired	-	302.70
Purchase of property, plant and equipment	8.12	(8.76)
Proceeds from sale of equipment	-	-
Acquisition of portfolio investments	-	-
Investment income	-	-
Net cash used in investing activities	8.12	293.94
Cash flows from financing activities		
Proceeds from issue of share capital	-	100.96
Proceeds from long-term borrowings	124.61	188.58
Proceeds from Short-term borrowings	(21.28)	-
Payment of Share Application Money	-	-
Share Capital Issue With Security Premium	-	-
Net cash used in financing activities	103.33	289.54
Net increase in cash and cash equivalents	(5.38)	3.31
Cash and cash equivalents at beginning of period	5.85	2.54
Cash and cash equivalents at end of period	0.47	5.85

For, Earum Pharmaceuticals Limited



PHUMISHTH PATEL
(Managing Director)
DIN -02516641

DATE : 30.10.2021
PLACE : AHMEDABAD

Notes:

- The revised financial results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors of the Company at their respective meetings held on 30.10.2021. The Statutory Auditors of the Company have carried out a Limited Review of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.
- The Company has migrated from BSE SME to BSE Main Board w.e.f September 16, 2021.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable. Beginning April 1, 2021, the Company has adopted Ind AS with a transition date of April 1, 2019. Accordingly, the figures for the quarter/ half year ended September 30, 2021 have been restated as per the Ind AS to make them comparable with the figures of the current quarter/ half year.
- The reconciliation for the net profit reported for the half year ended on September 30, 2020 in accordance with Indian GAAP to IND AS is given below:

Particulars	Rs (in Lakhs)
Net Profit/ Loss after tax as per Indian GAAP as at September 30, 2020	(151.94)
Add/Less: Adjustments	
Effect of measuring Investment at Fair Value through Profit & Loss Account	Nil
Impact on account of Adoption of Ind AS 116 "Lease"	Nil
Actuarial Gain/Loss on Employee Benefit Plan recognized in other Comprehensive income	Nil
Other Ind AS Adjustments	(10.77)
Total Comprehensive income for period as per IND-AS as on September 30, 2020	(162.71)

- The Company is operating Pharmaceutical Trading. The requirement of AS 17 "Segment Reporting", is not applicable to the company as it is engaged in single business segment.




6. During the period under review, the Company has allotted Bonus Shares on 11th August, 2021, in the ratio of 1:1, to the shareholders holding shares as on 10th August, 2021. (Record Date)
7. The figures for the previous periods have been regrouped / reclassified wherever necessary to confirm with the current period's classification.
8. After declaration of COVID-19 as pandemic by World Health Organization, its impact is already visible on multiple sectors in India and our Company is not an exception. The Management of the company has already carried out initial assessment of impact on business operations. This is a short-term disruption and company does not foresee medium to long term risks. The Company will continue as going concern and honor its financial commitments as and when they fall due for payment.
9. The results for the quarter ended September 30, 2021 are available on the website of BSE Limited i.e. www.bseindia.com and on the Company's website i.e. www.eaumpharma.com.

For EARUM PHARMACEUTICALS LIMITED

DATE: 30.10.2021
PLACE: AHMEDABAD




BHUMISHTH N.PATEL
MANAGING DIRECTOR
[DIN: 02516641]

Ref. No. :

Date :

LIMITED REVIEW REPORT

QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2021

Auditor's Report on Quarterly and Half Yearly Financial Results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


To,
The Board of Directors,
Earum Pharmaceuticals Limited

1. We have reviewed the accompanying Quarterly and half yearly standalone financial results of Earum Pharmaceuticals Limited ("the Company") for the Quarter and half year ended on 30th September, 2021 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These Quarterly and half yearly Financial Results have been prepared on the basis of the standalone financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these Standalone financial results based on our review of such financial statements, which have been prepared in accordance with the Accounting Standards notified under Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.
2. We conducted our review in accordance with the auditing standards generally accepted in India. These Standards require that we plan and perform the review to obtain moderate assurance about whether the Standalone financial statements are free of material misstatements. A review is limited preliminary to inquiries of company professionals and analytical procedures applied to the financial data and thus provide less assurance than an Audit. We have not performed an Audit and accordingly, we do not express as Audit Opinion.



3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that accompanying statement of unaudited standalone financial results prepared in accordance with recognition and measurement principals laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting principal and policies had not disclosed the information recognised to be disclosed in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed or that it contains any material misstatement except GST Proceeding.

Place: Ahmedabad
Date: 30/10/2021



For, M/s J M Patel & Bros.,
CHARTERED ACCOUNTANTS
FRN.: 107707W

Jashwant M Patel
CA JASHWANT M PATEL
(PROPRIETOR)
M. NO.: 030161
UDIN: 21030161AAAAXM3892